Grifols SA
Company Profile
Business description
Grifols SA one of is global specialty plasma therapeutics companies developing, manufacturing and distributing a broad range of biological medicines based on plasma derived proteins. Plasma derivatives are proteins found in human plasma, which once isolated and purified, have therapeutic value. These protein-based therapies extend and enhance the lives of individuals who suffer from chronic and acute, often life-threatening, conditions, including primary and secondary immunological deficiencies, Chronic Inflammatory Demyelinating Polyneuropathy, immune-mediated ITP. Products and services are used to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases and a range of other medical conditions. Majority of revenue is from USA.
Contact
Avinguda de la Generalitat, 152-158
Parc de Negocis Can Sant Joan
Sant Cugat del Valles
Barcelona08174
ESPT: +34 935710500
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2025
Employees
23,822
Stocks News & Analysis
stocks
6 undervalued stocks with low beta
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 8,639.30 | 1.50 | 0.02% |
CAC 40 | 7,779.72 | 8.38 | -0.11% |
DAX 40 | 23,933.23 | 104.96 | -0.44% |
Dow JONES (US) | 42,215.73 | 117.03 | 0.28% |
FTSE 100 | 8,716.45 | 9.56 | -0.11% |
HKSE | 23,220.87 | 352.51 | -1.50% |
NASDAQ | 19,175.87 | 74.93 | 0.39% |
Nikkei 225 | 37,917.38 | 515.60 | -1.34% |
NZX 50 Index | 12,378.17 | 96.86 | 0.79% |
S&P 500 | 5,912.17 | 23.62 | 0.40% |
S&P/ASX 200 | 8,413.90 | 4.10 | 0.05% |
SSE Composite Index | 3,344.72 | 18.72 | -0.56% |